Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical TrialMichael Brownstein, Stephanie Lowenhaupt, Jon Yankey et al.|Journal of Clinical Medicine|2020Cited by 32
Operational Development and Launch of an Adaptive Platform Trial in Amyotrophic Lateral Sclerosis: Processes and Learnings From the First Four Regimens of the <scp>HEALEY ALS</scp> Platform TrialBrittney Harkey, Sofia DiStefano, Jaclyn Pagliaro et al.|Muscle & Nerve|2025Cited by 6